332 related articles for article (PubMed ID: 2791500)
41. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1992). I. Susceptibility distribution].
Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
Jpn J Antibiot; 1995 Nov; 48(11):1627-57. PubMed ID: 8558754
[TBL] [Abstract][Full Text] [Related]
42. In-vitro activity of four new fluoroquinolones.
García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
[TBL] [Abstract][Full Text] [Related]
43. In vitro activity of T-3761, a new fluoroquinolone.
Muratani T; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1992 Oct; 36(10):2293-303. PubMed ID: 1332594
[TBL] [Abstract][Full Text] [Related]
44. The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone.
Wise R; Andrews JM; Brenwald N
J Antimicrob Chemother; 1993 Jan; 31(1):73-80. PubMed ID: 8383104
[TBL] [Abstract][Full Text] [Related]
45. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
[TBL] [Abstract][Full Text] [Related]
46. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution].
Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F
Jpn J Antibiot; 1996 May; 49(5):465-93. PubMed ID: 8752862
[TBL] [Abstract][Full Text] [Related]
47. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.
Fung-Tomc J; Minassian B; Kolek B; Washo T; Huczko E; Bonner D
J Antimicrob Chemother; 2000 Apr; 45(4):437-46. PubMed ID: 10747819
[TBL] [Abstract][Full Text] [Related]
48. Antibacterial activity of lomefloxacin.
Leigh DA; Tait S; Walsh B
J Antimicrob Chemother; 1991 May; 27(5):589-98. PubMed ID: 1885417
[TBL] [Abstract][Full Text] [Related]
49. In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents.
Wise R; Andrews JM; Ashby JP; Matthews RS
Antimicrob Agents Chemother; 1988 May; 32(5):617-22. PubMed ID: 3134843
[TBL] [Abstract][Full Text] [Related]
50. In vitro antimicrobial activity and postantibiotic effect of lomefloxacin, a new difluoroquinolone.
Molinari G; Bandelloni R; Paglia P; Debbia E; Schito GC
Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):53S-56S. PubMed ID: 2791499
[TBL] [Abstract][Full Text] [Related]
51. The comparative in-vitro activity of ofloxacin.
Grüneberg RN; Felmingham D; O'Hare MD; Robbins MJ; Perry K; Wall RA; Ridgway GL
J Antimicrob Chemother; 1988 Sep; 22 Suppl C():9-19. PubMed ID: 3182468
[TBL] [Abstract][Full Text] [Related]
52. [In vitro evaluation of lomefloxacin].
Dette GA; Knothe H
Arzneimittelforschung; 1989 Aug; 39(8):832-5. PubMed ID: 2818672
[TBL] [Abstract][Full Text] [Related]
53. Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients.
Rolston KV; Ho DH; LeBlanc B; Gooch G; Bodey GP
Eur J Clin Microbiol Infect Dis; 1988 Oct; 7(5):684-6. PubMed ID: 3143585
[TBL] [Abstract][Full Text] [Related]
54. In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent.
Guinea J; Robert M; Gargallo-Viola D; Xicota MA; Garcia J; Tudela E; Esteve M; Coll R; Pares M; Roser R
Antimicrob Agents Chemother; 1993 Apr; 37(4):868-74. PubMed ID: 8388202
[TBL] [Abstract][Full Text] [Related]
55. In vitro activity of lomefloxacin against multiply resistant Pseudomonas aeruginosa, Enterobacter cloacae, and Staphylococcus epidermidis.
DiVincenzo CA; Shatzer KL; Venezio FR
Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):13S-16S. PubMed ID: 2507220
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of the bactericidal activity of temafloxacin.
Jacobs MR
Am J Med; 1991 Dec; 91(6A):31S-34S. PubMed ID: 1662893
[TBL] [Abstract][Full Text] [Related]
57. Comparative in vitro activity of a new quinolone, AM-1091.
Neu HC; Novelli A; Chin NX
Antimicrob Agents Chemother; 1989 Jul; 33(7):1036-41. PubMed ID: 2675753
[TBL] [Abstract][Full Text] [Related]
58. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
Oliveira AD; D'Azevedo PA; Francisco W
Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812
[TBL] [Abstract][Full Text] [Related]
59. In-vitro activity of WIN 57273 compared to the activity of other fluoroquinolones and two beta-lactam antibiotics.
Chin NX; Neu HC
J Antimicrob Chemother; 1991 Jun; 27(6):781-91. PubMed ID: 1657856
[TBL] [Abstract][Full Text] [Related]
60. In vitro activity of the two new 4-quinolones A56619 and A56620 against Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum and Gardnerella vaginalis.
Tjiam KH; Wagenvoort JH; van Klingeren B; Piot P; Stolz E; Michel MF
Eur J Clin Microbiol; 1986 Oct; 5(5):498-501. PubMed ID: 3096726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
